Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2009

01-08-2009 | Preclinical Study

Down-regulation of tumor suppressor gene FEZ1/LZTS1 in breast carcinoma involves promoter methylation and associates with metastasis

Authors: Ling Chen, Zhengmao Zhu, Xiaodong Sun, Xue-Yuan Dong, Jia Wei, Feng Gu, Yu-Lan Sun, Jun Zhou, Jin-Tang Dong, Li Fu

Published in: Breast Cancer Research and Treatment | Issue 3/2009

Login to get access

Abstract

FEZ1/LZTS1 is a tumor suppressor gene located in chromosomal band 8p22, and methylation has been identified as a mechanism for its loss of function in tumors. Chromosomal deletion at 8p22 is also frequent in breast cancer. We therefore examined whether LZTS1 plays a role in breast cancer. We analyzed expression of LZTS1 at both the RNA and protein levels, and promoter methylation in a number of primary tumors and cell lines from breast cancer. We also examined the association between LZTS1 expression and different clinicopathological parameters of breast cancer. We found that the expression of LZTS1 mRNA was reduced in 25 of 50 (50%) primary tumors and 29 of 30 (97%) breast cancer cell lines. Immunohistochemical staining showed that LZTS1 protein was absent or down-regulated in 72 (72%) of 100 primary breast carcinomas. Reduced expression of LZTS1 at either the RNA or protein level was significantly correlated with lymph node metastases (< 0.05). DNA methylation analysis revealed that the LZTS1 gene was frequently methylated in both cell lines and primary tumors from breast cancer, and the extent of DNA methylation was correlated with reduced expression of the gene. These findings suggest that LZTS1 plays a role in the development and progression of breast cancer at least through promoter methylation-mediated transcriptional downregulation.
Literature
1.
2.
go back to reference Toyooka S, Fukuyama Y, Wistuba II et al (2002) Differential expression of FEZ1/LZTS1 gene in lung cancers and their cell cultures. Clin Cancer Res 8:2292–2297PubMed Toyooka S, Fukuyama Y, Wistuba II et al (2002) Differential expression of FEZ1/LZTS1 gene in lung cancers and their cell cultures. Clin Cancer Res 8:2292–2297PubMed
3.
go back to reference Vecchione A, Ishii H, Shiao YH et al (2001) Fez1/lzts1 alterations in gastric carcinoma. Clin Cancer Res 7:1546–1552PubMed Vecchione A, Ishii H, Shiao YH et al (2001) Fez1/lzts1 alterations in gastric carcinoma. Clin Cancer Res 7:1546–1552PubMed
4.
go back to reference Vecchione A, Ishii H, Baldassarre G et al (2002) FEZ1/LZTS1 is down-regulated in high-grade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma cells. Am J Pathol 160:1345–1352PubMed Vecchione A, Ishii H, Baldassarre G et al (2002) FEZ1/LZTS1 is down-regulated in high-grade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma cells. Am J Pathol 160:1345–1352PubMed
10.
go back to reference Ono K, Uzawa K, Nakatsuru M et al (2003) Down-regulation of FEZ1/LZTS1 gene with frequent loss of heterozygosity in oral squamous cell carcinomas. Int J Oncol 23:297–302PubMed Ono K, Uzawa K, Nakatsuru M et al (2003) Down-regulation of FEZ1/LZTS1 gene with frequent loss of heterozygosity in oral squamous cell carcinomas. Int J Oncol 23:297–302PubMed
15.
Metadata
Title
Down-regulation of tumor suppressor gene FEZ1/LZTS1 in breast carcinoma involves promoter methylation and associates with metastasis
Authors
Ling Chen
Zhengmao Zhu
Xiaodong Sun
Xue-Yuan Dong
Jia Wei
Feng Gu
Yu-Lan Sun
Jun Zhou
Jin-Tang Dong
Li Fu
Publication date
01-08-2009
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-0147-6

Other articles of this Issue 3/2009

Breast Cancer Research and Treatment 3/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine